Title Page

Impaired Pulmonary Arterial Vasoconstriction and Nitric Oxide-Mediated Relaxation Underlie Severe Pulmonary Hypertension in Sugen-Hypoxia Rat Model

Helen Christou, Hannes Hudalla, Zoe Michael, Evgenia J. Filatava,

Jun Li, Minglin Zhu, Jose S. Possomato-Vieira, Carlos Dias-Junior,

Stella Kourembanas, Raouf A. Khalil

Department of Pediatric Newborn Medicine (HC, HH, ZM, EJF, SK), and Division of Vascular and Endovascular Surgery (JL, MZ, JSP, CD, RAK), Brigham and Women's Hospital, and Division of Newborn Medicine, Children's Hospital (HC,SK), Harvard Medical School, Boston, MA 02115, USA; and Department of Neonatology, Children's University Hospital, Heidelberg, 69120, Germany (HH)

Running Title Page

Running Title: Pulmonary Vascular Dysfunction in Pulmonary Hypertension

Correspondence and Reprints:

Raouf A Khalil, MD, PhD

Harvard Medical School

Brigham and Women's Hospital

Division of Vascular Surgery

75 Francis Street

Boston, MA 02115

Tel : (617) 525-8530

Fax : (617) 264-5124

E-mail : raouf_khalil@hms.harvard.edu

Document Statistics

Number of Text Pages	38
Number of Tables	1
Number of Figures	10
Number of References	65
Number of Words in Abstract	250
Number of Words in Introduction	500
Number of Words in Discussion	2500

List of Non-Standard Abbreviations:

Ach   acetylcholine

ET-1   endothelin

FI   Fulton's index

L-NAME N_ω-nitro-L-arginine methyl ester

LVSP   left ventricular systolic pressure

NO   nitric oxide

NOS   nitric oxide synthase

ODQ   1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one

PDE-5   phosphodiesterase-5

PGI_2 prostacyclin

PH   pulmonary hypertension

Phe   phenylephrine

RVH   right ventricular hypertrophy

RVSP   right ventricular systolic pressure

SNP   sodium nitroprusside

VSMC   vascular smooth muscle cell

ABSTRACT

Pulmonary vasoreactivity could determine the responsiveness to vasodilators and in turn the prognosis of pulmonary hypertension (PH). We hypothesized that pulmonary vasoreactivity is impaired, and examined the underlying mechanisms, in the sugen-hypoxia rat model of severe PH. Male Sprague-Dawley rats were injected with sugen (20 mg/kg sc) and exposed to hypoxia (9% O_2) for 3 weeks followed by 4 weeks in normoxia (Su/Hx), or treated with sugen alone (Su) or hypoxia alone (Hx) or neither (Nx). After hemodynamic measurements, the heart was assessed for right ventricular hypertrophy (Fulton's Index), the pulmonary artery, aorta and mesenteric arteries were isolated for vascular function studies, and contractile markers were measured in pulmonary artery using quantitative PCR. Other rats were used for morphometric analysis of pulmonary vascular remodeling. Right ventricular systolic pressure and Fulton's Index were higher in Su/Hx vs Su, Hx and Nx rats. Pulmonary vascular remodeling was more prominent in Su/Hx vs Nx rats. In pulmonary artery rings, contraction to high KCl (96 mM) was less in Su/Hx vs Nx and Su, and phenylephrine-induced contraction was reduced in Su/Hx vs Nx, Hx and Su. Acetylcholine (ACh)-induced relaxation was less in Su/Hx vs Nx and Hx, suggesting reduced endothelium-dependent vasodilation. ACh relaxation was inhibited by NOS and guanylate cyclase blockade in all groups, suggesting a role of the NO-cGMP pathway. Nitrate/nitrite production in response to ACh was less in Su/Hx vs Nx, supporting reduced endothelial NO production. Sodium nitroprusside (10^{-8} M) caused less relaxation in Su/Hx vs Nx, Hx and Su, suggesting decreased responsiveness of vascular smooth muscle (VSM) to vasodilators. Neither contraction nor relaxation differed in the aorta or mesenteric arteries of all groups. PCR analysis showed decreased expression of contractile markers in pulmonary artery of Su/Hx vs Nx. The reduced responsiveness to vasoconstrictors and NO-mediated vasodilation in the pulmonary, but not systemic, vessels may be an underlying mechanism of severe PH in Su/Hx rats, and appears to involve attenuation of the NO relaxation pathway and a switch of pulmonary VSM cells to a synthetic less reactive phenotype.

4

INTRODUCTION

Pulmonary Hypertension (PH) is a heterogeneous clinical syndrome with poor prognosis. PH involves vasoconstriction and progressive structural remodeling of the pulmonary arterioles resulting in right ventricular hypertrophy and failure. However, the underlying pathogenetic mechanisms of PH remain incompletely understood. Although both pulmonary vasoconstriction and obliteration of the pulmonary arterioles contribute to increased pulmonary vascular resistance, invasive hemodynamic studies have shown that only a small percentage of patients have a reactive component (Tonelli et al., 2010). Despite this finding, all current available treatments for PH act by inducing pulmonary vasodilation with a smaller effect on structural remodeling. Accumulating evidence from studies in preclinical models of PH and in human patients support that a phenotypic switch of pulmonary vascular smooth muscle cells (VSMCs) from contractile to synthetic phenotype underlies, at least in part, the pathophysiology of PH (Michelakis et al., 2002; McMurtry et al., 2004; McMurtry et al., 2005; Bonnet et al., 2007; Li et al., 2009). Our previous studies have shown impaired vasoconstriction and vascular relaxation in pulmonary arteries in the hypoxic and monocrotaline-treated models of PH, and suggested a role of phenotypic switch in VSMCs in the impaired pulmonary vascular responses (Mam et al., 2010). We have also shown that induction of modest acidosis by treating the hypoxic and monocrotaline rats with ammonium chloride (NH_4Cl) *in vivo* improves right ventricular systolic pressure and pulmonary vascular responsiveness to both vasoconstrictors and vasodilators, supporting that reversing or halting the VSMC phenotypic switch would improve pulmonary arterial function in PH (Christou et al., 2012). Both the hypoxic and the monocrotaline models of PH have limitations and may not fully recapitulate the human condition (Stenmark et al., 2009). In order to further advance the VSMC phenotypic switch theory as a promising therapeutic target in PH, it is imperative to determine that such mechanisms underlie the pulmonary arterial pathology in models that more closely resemble the pathology in human PH.

5

The sugen-hypoxia (Su/Hx) rat model of experimental PH was first described by Taraseviciene-Stewart and co-workers, as a biologically more relevant model for human PAH. This model more closely recapitulates the human pathology than other rodent models, partly due to its progressive nature, formation of plexiform lesions, and ultimate lethality (Taraseviciene-Stewart et al., 2001; Abe et al., 2010; de Raaf et al., 2014). Sugen 5416 (semaxanib) is an anti-neoplastic drug with tyrosine kinase inhibitor and vascular endothelial growth factor receptor (VEGFR)-2 inhibitor properties (O'Farrell et al., 2004). Sugen 5416 in combination with hypoxia in rats and mice sets off a cascade of events that lead to structural remodeling of the pulmonary arterioles and progressively worsening hemodynamics and plexiform lesions that are not seen in any other model of PH (Zhou et al., 2016; Aiello et al., 2017). As such, this model is a useful tool to study the underlying pathogenetic mechanisms and identify novel therapeutic targets. However, complete understanding of the underlying pulmonary vascular dysfunction mechanisms of PH in this model is lacking. Understanding the vascular mechanisms involved in the Su/Hx model of severe PH should help develop targeted vascular protective therapies for this life-threatening disease. However, the changes in the reactivity of the pulmonary arteries to vasoconstrictor and vasodilator stimuli and the underlying mechanisms have not been systematically studied in this model. We designed the present study to test the hypothesis that Su/Hx-induced PH involves specific abnormalities in the pulmonary arterial responsiveness to vasoconstrictor and vasodilator stimuli, and to examine the mechanisms underlying these abnormalities. We studied the hemodynamics and vascular function in three separate vascular beds, the pulmonary artery, the aorta and mesenteric arteries, isolated from Su/Hx rat model of severe PH, in order to determine: 1) Whether the responsiveness of the pulmonary artery to vasoconstrictor or vasodilator stimuli is impaired in severe PH, 2) Whether the impaired pulmonary arterial relaxation in severe PH involve the endothelium-dependent NO-cGMP pathway, and 3) Whether the impaired pulmonary arterial responsiveness to vasoconstrictors and vasodilators involve extensive vascular remodeling and phenotypic switch in VSM cells.

Materials and Methods

Animals and Exposures. Eight-week-old (200-250g) male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) were housed in the animal facility in 12 hr/12 hr light/dark cycle, at 22±1°C ambient temperature and maintained on *ad libitum* normal Purina Rodent Chow (Purina, St. Louis, MO) and tap water. After 2-3 days of acclimatization, animals were injected with 20 mg/kg of Sugen 5416 subcutaneously (Sigma) or equal volume of vehicle (DMSO) and either kept in normoxia or exposed to hypoxia at 9% O_2 inside a chamber where O_2 was controlled to within a 0.2% range by an OxyCycler controller (BioSpherix, Redfield, NY) as previously described (Mam et al., 2010; Christou et al., 2012). The controller injected nitrogen into the chamber to maintain the appropriate FiO_2, and ventilation was adjusted to remove CO_2 so that it did not exceed 5,000 ppm (0.5%). We observed better ventilation of the chamber with the higher flow of nitrogen needed to maintain O_2 at 9% as opposed to 10% and therefore opted to use 9% for our studies. The duration of hypoxic exposure was 3 weeks, followed by normoxia for 4 weeks. Normoxic rats breathed air for 7 weeks under otherwise identical conditions. All measurements were taken and the animals were sacrificed 7 weeks after the start of the experiment. Thus these treatments produced 4 animal groups, namely normoxia (Nx), sugen alone (Su), hypoxia alone (Hx), and sugen+hypoxia (Su/Hx) (Fig. 1A). All experimental procedures followed the guidelines of the American Physiological Society and the National Institutes of Health, and were approved by the Institutional Animal Care and Use Committee at the Brigham and Women Hospital.

Right and Left Ventricular Systolic Pressure (RVSP and LVSP) Measurements. Animals were anesthetized with 3% isoflurane inhalation, intubated through a tracheostomy and mechanically ventilated on a rodent ventilator (Harvard Apparatus, tidal volume 1ml/100g body weight, 60 breaths per minute). A small transverse incision was made in the abdominal wall and the diaphragm was exposed and opened. A 23-gauge butterfly needle with tubing

7

attached to a pressure transducer was inserted in an open-chest approach first into the right ventricle and then into the left ventricle and pressure measurements were recorded with PowerLab monitoring hardware and software (ADInstruments, Colorado Springs, CO). Animals with heart rates less than 300 beats per minute were considered over-anesthetized and their RVSP and LVSP measurements were excluded. Mean RVSP and LVSP over the first 10 stable heartbeats were recorded.

Tissue Isolation. Animals were anesthetized with isoflurane and while in deep anesthesia, they were sacrificed by exsanguination and immediate harvesting of vital organs. In euthanized rats, the thoracic cavity was opened, and the heart, lung, pulmonary arteries, and thoracic aorta were rapidly excised. The abdominal cavity was then opened and the mesentery and mesenteric arterial arcade were excised and placed in oxygenated Krebs solution. In separate experiments, the lungs were perfused and inflated and harvested for histologic analysis.

Right Ventricular Weight and Fulton's Index. The heart was carefully dissected from surrounding tissues, and both ventricles were isolated and weighed. The right ventricular wall was carefully dissected and weighed, then the remaining left ventricular wall and ventricular septum were weighed. Fulton's Index was calculated as the ratio of right ventricular weight/(left ventricular + septum weight).

Vascular Preparation. The right and left pulmonary artery, the thoracic aorta and 2nd order mesenteric arteries were carefully dissected and cleaned of connective tissue under microscopic visualization, and cut into 3 mm-wide rings. For endothelium-intact segments extreme care was taken to minimize injury to the endothelium. For endothelium-denuded segments, the endothelium was removed by scraping the vessel interior five times around the tip of forceps (for aorta and pulmonary artery) or around thin tungsten wire (for mesenteric

8

artery). Different segments from each vascular bed were used for different experimental protocols. The remainder of the vessels was used to measure nitrate/nitrite production.

Isometric Vascular Contraction/Relaxation. Vascular segments from the same rat were suspended between two stainless-steel or tungsten wire hooks, one hook was fixed at the bottom of a tissue bath and the other hook was connected to a Grass force transducer (FT03, Astro-Med Inc., West Warwick, RI). Large caliber stainless-steel wires are more suitable for larger vessels (aorta and pulmonary artery), while small caliber tungsten wire are more suitable for smaller vessels with narrower diameter (mesenteric artery). Stainless-steel can not be stretched into very thin wires, and large caliber tungsten wires are not malleable enough and easy to break. Extra-lobar first branch right and left pulmonary arteries, thoracic aorta and mesenteric artery segments were stretched under 1 g, 2 g or 0.5 g of resting tension, respectively, as determined by preliminary tension-contraction curves to KCl. We compared the pulmonary arteries to the aorta because of their close anatomical proximity. In order to compare the pulmonary arteries, with their role in the control of pulmonary arterial pressure, to a more relevant systemic artery, with a role in the control of the systemic arterial pressure, we also studied the mesenteric arteries. The tissues were allowed to equilibrate for 45 min in a temperature controlled, water-jacketed tissue bath, filled with 50 ml Krebs solution continuously bubbled with 95% O_2 5% CO_2 at 37°C. Our aim was to compare vascular function in three different vascular beds; the pulmonary artery, the aorta and mesenteric artery, under the same conditions. Lower oxygen concentration may affect the solution pH and cause acidosis, which will require further buffering in order to adjust the solution to a more neutral pH. Therefore, to facilitate comparison and to minimize potential confounding factors all vessels were treated in a similar fashion and studied in 95% O_2 5% CO_2. The changes in isometric contraction were recorded on a Grass polygraph (Model 7D, Astro-Med).

After tissue equilibration, a control contraction in response to 96 mM KCl was elicited. Once maximum KCl contraction was reached the tissue was rinsed with Krebs 3 times, 10 min

each. Vascular segments were stimulated with increasing concentrations of phenylephrine (Phe, 10^{-9} to 10^{-5} M), concentration-contraction curves were constructed, and the maximal Phe contraction and the pED_{50} (-log M) were calculated. In other experiments, the tissues were precontracted with submaximal Phe concentration (3×10^{-7} or 6×10^{-7} M), increasing concentrations (10^{-9} to 10^{-5} M) of acetylcholine (ACh) were added and the % relaxation of Phe contraction was measured. Parallel contraction and relaxation experiments were performed in endothelium-intact vascular rings pretreated with the NOS inhibitor N^{ω}-nitro-L-arginine methyl ester (L-NAME, 3×10^{-4} M) or the guanylate cyclase inhibitor 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 10^{-5} M) for 15 min. NO diffuses into VSM where it activates guanylate cyclase, increases cGMP and promotes relaxation. L-NAME is a competitive substrate that competes with L-arginine for binding with NOS, and because the endogenous concentration of L-arginine is high, very high concentrations of L-NAME (3×10^{-4} M) are needed to block NOS and the NO-cGMP pathway. In contrast, ODQ directly inhibits guanylate cyclase at much lower concentration (10^{-5} M) and could be more efficient in blocking the NO-cGMP pathway. Phe contraction and ACh relaxation were also measured in endothelium-denuded vessels. The endothelium was removed from blood vessels of the different animal groups using the same experimental protocol. The endothelium was removed by rubbing the vessel interior 5 times around the tip of sharp forceps. Complete removal of the endothelium was verified by the absence of ACh-induced relaxation. Extreme care was taken to avoid damage to the underlying smooth muscle layer. Any endothelium-denuded vessels that showed more than 30% reduction in contraction to Phe or KCl compared to that in control endothelium-intact vessels were removed from the study. In other experiments the relaxation to increasing concentrations (10^{-9} to 10^{-5} M) of the exogenous NO donor sodium nitroprusside (SNP) was measured in vascular rings precontracted with Phe in order to test the ability of VSM to respond to vasodilators, Individual ACh and SNP concentration-relaxation curves were further analyzed using non-linear regression, sigmoidal dose-response curves were fitted using the least squares method, and ACh and SNP pED_{50} were calculated.

Nitrate/Nitrite (NOx) Production. Endothelium-intact aortic, pulmonary artery or mesenteric arterial segments were incubated in normal Krebs for 30 min to measure basal NO production then stimulated with ACh (10^{-8} to 10^{-5} M) for 30 min and the incubation solution was assayed for the stable end product of NO, NO_2^- using Griess reagent (Promega, Madison, WI) (Crews et al., 2000; Mazzuca et al., 2014).

Lung Histology and Morphometric Analysis. In a subset of experimental animals, the lungs were perfused and inflated with cold 4% paraformaldehyde (PFA), excised, and fixed in 4% PFA overnight at 4° C followed by paraffin embedding. Lung sections (6 μm) were stained with hematoxylin and eosin and examined with light microscopy by two independent investigators (EJF and HC) in a blinded fashion. Images of the arterioles were captured with a microscope digital camera system (Nikon) and analyzed using an image analysis program (ImageJ). Arterioles of comparable size (50-100 μm diameter) from the lungs of 5 different rats from each experimental group were evaluated. The percent wall thickness was determined by dividing the area occupied by the vessel wall by the total cross sectional area of the arteriole as previously reported (Christou et al., 2000). This method accounts for uneven vessel wall thickness and areas that have obliquely sectioned pulmonary arterioles.

Gene expression analysis. In a subset of experimental animals pulmonary arteries were harvested for RNA isolation. The right and left pulmonary artery were carefully dissected as distally as possible and cleaned of connective tissue. The pulmonary trunk was not used for gene expression analysis. RNA was isolated using TRIzol reagent (Invitrogen Life Technologies) and quantified using a NanoDrop 2000c spectrophotometer (NanoDrop Technologies). Samples were treated with DNAse I (Sigma) to digest genomic DNA and poly(A)$^+$ mRNA was transcribed to complementary DNA (cDNA) using SuperScript III (Invitrogen Life Technologies). Relative mRNA transcript levels were analyzed with a

11

StepOnePlus RT-PCR cycler (Applied Biosystems) using iTaq Universal SYBR Green Supermix (Biorad). Primers were designed across exon-exon junctions and specific for all transcript variants where possible using nBLAST (NCBI) and PrimerQuest Tool (Integrated DNA Technologies, IDT) (Table 1). Expression was analyzed with the ΔΔCt method. Ct values of target genes were normalized to the mean expression of the reference genes *Nup133* (nucleoporin 133) and *Gapdh* using the equation $\Delta Ct = Ct_{target} - ((Ct_{Nup133} + Ct_{GAPDH})/2)$. Data were expressed as relative mRNA expression ($2^{-\Delta\Delta Ct}$).

Solutions and Drugs. Krebs solution contained (in mM): NaCl 120, KCl 5.9, $NaHCO_3$ 25, NaH_2PO_4 1.2, dextrose 11.5, $CaCl_2$ 2.5, $MgCl_2$ 1.2, at pH 7.4, and bubbled with 95% O_2 and 5% CO_2. High 96 mM KCl solution was prepared as Krebs solution with equimolar substitution of NaCl with KCl. Stock solutions of Phe, ACh, L-NAME and SNP (10^{-1} M, Sigma, St. Louis, MO) were prepared in distilled water. Stock solution of ODQ (10^{-1} M) was prepared in DMSO. Final concentration of DMSO in experimental solution was <0.1%. All other chemicals were of reagent grade or better.

Statistical Analysis. Data from different groups were analyzed by ANOVA and presented as means±SEM with "n" representing the number of rats per group. Hemodynamics, tissue histology, and quantitative morphometry data were analyzed with ANOVA and Tukey's *post hoc* analysis. For vascular reactivity experiments, individual concentration-contraction or concentration-relaxation curves were constructed, sigmoidal curves were fitted to the data using the least squares method, and the pEC_{50} values ($-\log EC_{50}$, drug concentration evoking half-maximal response) were measured using Prism (v.5.01; GraphPad Software, San Diego, CA). Data were first analyzed using ANOVA with multiple classification criteria [rat group (Nx vs. Su, Hx and Su/Hx), condition of vascular endothelium (denuded vs. intact), vessel treatment (treated with L-NAME or ODQ vs. nontreated control tissues).

When a statistical difference was observed, the data were further analyzed using Bonferroni's *post-hoc* test for multiple comparisons. Student's unpaired *t*-test and Mann-Whitney test for non-parametric analyses were used for comparison of two means. Differences were considered statistically significant if P < 0.05.

RESULTS

Hemodynamic measurements

Hemodynamic measurements in the Su/Hx animals revealed significantly increased RVSP at the 7 week time point, compared to Nx and Hx animals (Fig. 1B). Since prior publications demonstrated that some animals develop PH after Su injection alone (without hypoxia) we included this experimental group on our study design and found that Su animals had an intermediate phenotype with significantly higher RVSP compared to Nx animals. However, RVSP was significantly higher in Su/Hx compared to Su alone group. In contrast, LVSP, an indicator of the blood pressure in the systemic circulation, was not significantly different among the different experimental groups (Fig. 1C).

The Fulton's Index and RV/body weight ratio, indicators of RV hypertrophy, were significantly higher in Su/Hx compared to Nx and Hx animals (Fig. 1D and 1E). The Su alone animals had significantly higher Fulton's index and RV/body weight ratio than Nx animals. However, Fulton's index and RV/body weight were significantly higher in the Su/Hx compared to Su alone group.

Vascular Function Studies

In endothelium-intact pulmonary artery rings of control Nx rats, membrane depolarization by 96 mM KCl caused significant contraction. The KCl-induced contraction was not different in pulmonary arteries of Hx rats, slightly increased in Su rats and significantly reduced in Su/Hx rats (Fig. 2A). In contrast, KCl-induced contraction was not significantly different in the aorta or mesenteric arteries of the different groups of rats (Fig. 2B, 2C). To test if the reduction in

pulmonary artery contraction in the Su/Hx group is due to the release of endothelium-derived vasodilators, we examined the KCl response in endothelium denuded pulmonary artery. Similar to the observation in endothelium-intact pulmonary arteries, KCl contraction remained markedly reduced in endothelium-denuded vessels of Su/Hx compared to Nx and Su groups (Fig. 2D), suggesting that the reduction in contraction is endothelium-independent and involves reduction in the mechanisms of VSMC contraction. Interestingly, KCl contraction was also significantly decreased in endothelium-denuded vessels of the Hx rats compared to Nx controls (Fig. 2D). Previous studies have shown enhanced pressor response to endothelin-1 in Hx rats (Adnot et al., 1991). It is likely that during Hx there is increased release of endothelium-derived contracting factors such as endothelin-1, and that the contribution of these endothelium-derived contracting factors is abolished in endothelium-denuded vessels, resulting in a reduced contractile response. In contrast, KCl contraction was not different in endothelium-denuded aorta or mesenteric artery of the different groups (Fig. 2E, 2F).

In pulmonary artery rings of Nx rats, the α-adrenergic agonist phenylephrine (Phe) caused concentration-dependent contraction that reached a maximum at 10^{-5} M concentration (Fig. 3A). The Phe-induced contraction of pulmonary artery in g/mg was not different in Hx rats, slightly enhanced in Su alone rats but significantly reduced in Su/Hx compared to Nx and Su rats (Fig. 3A). In contrast, Phe contraction in g/mg was not different in the aorta or mesenteric artery of the different groups (Fig. 3B, 3C). When Phe contraction was presented as % of max, and the ED_{50} was calculated, Phe appeared to be equally potent in the pulmonary arteries of Nx, Hx and Su rats, but the Phe concentration-response curve was shifted to the right, suggesting lower Phe potency in Su/Hx compared Nx, Hx, and Su rats (Fig. 3D). In contrast, in the aorta and mesenteric arteries, the Phe-induced concentration-response curves and ED50 did not appear to be different among the different groups (Fig. 3E, 3F).

Because the Phe response varied in different vessels from the same group, we also presented Phe contraction as % of control KCL contraction in the same vessel. Phe response as % of control KCl contraction was reduced in pulmonary artery of Su/Hx compared to Nx,

Hx, and Su rats (Fig. 3G). In contrast, the Phe contraction as % of control KCl contraction was not significantly different inthe aorta or mesenteric artery of the different groups (Fig. 3H, 3I).

We tested the role of the endothelium in the reduced Phe contraction in the Su/Hx rats. Pretreatment of pulmonary artery segments with the NOS inhibitor L-NAME (3×10^{-4} M) or the guanylate cyclase inhibitor ODQ for 15 min or endothelium removal showed a small but not significant change in Phe contraction in Nx, Hx, Su, or Su/Hx rats (Fig. 4A, 4B, 4C, 4D). When the Phe response was presented as % of maximum contraction, treatment with L-NAME or ODQ did not significantly change the Phe response in Nx, Hx, or Su/Hx rats, while ODQ significantly enhanced the Phe response in Su rats (Fig. 4E, 4F, 4G, 4H). Assuming that KCl contraction is mainly due to Ca^{2+} entry into vascular smooth muscle, then any enhancement of Phe contraction relative to KCl contraction would suggest possible activation of Ca^{2+} sensitization pathways such as PKC or Rho kinase (Ringvold and Khalil, 2017). L-NAME and ODQ slightly but significantly enhanced Phe contraction relative to KCl in Nx, but not Hx rats (Fig. 4I, 4J). ODQ caused marked enhancement of Phe contraction relative to KCl in Su and Su/Hx rats (Fig. 4K, 4L). The greater effects of ODQ vs L-NAME in enhancing Phe contraction could be related to its direct inhibition of guanylate cyclase and greater efficiency in blocking the NO-cGMP pathway.

Acetylcholine (ACh) caused concentration-dependent relaxation in Phe precontracted pulmonary artery rings of Nx rats that reached a maximum at 10^{-5} M concentration. ACh-induced pulmonary artery relaxation was not different in Hx rats, partially reduced in Su rats and significantly reduced in Su/Hx compared to Nx and Hx rats (Fig. 5A), suggesting either reduced production of, or decreased responsiveness to, endothelium-derived vasodilators such as NO in the setting of experimental PH. In comparison, ACh relaxation was not significantly different in Phe precontracted aorta and mesenteric artery rings of the different groups of rats (Fig. 5B, 5C).

In pulmonary artery of Nx, Su, and Hx, the NOS inhibitor L-NAME, and the guanylate cyclase inhibitor ODQ or endothelium-removal abolished ACh-induced relaxation, suggesting

15

the involvement of endothelium-dependent NO-cGMP pathway (Fig. 6A, 6B, 6C)). Pretreatment with L-NAME or ODQ or endothelium-removal also abolished the small ACh-induced relaxation in pulmonary artery of Su/Hx rats (Fig. 6D), suggesting that the vasorelaxation response to ACh in experimental PH is mediated by the NO-cGMP pathway.

In endothelium intact pulmonary artery segments ACh caused concentration-dependent increases in nitrate-nitrite production that were reduced in Hx, Su and Su/Hx rats compared to Nx rats (Fig. 7A). In contrast, nitrate/nitrite production in response to ACh was not significantly altered in the aorta and mesenteric artery of the different groups (Fig. 7B, 7C).

In pulmonary artery segments precontracted with submaximal Phe concentration, the exogenous NO donor sodium nitroprusside (SNP) caused concentration-dependent relaxation that was not different in Hx or Su rats compared to Nx arts, but was significantly reduced in Su/Hx rats compared to Nx, Hx and Su rats particularly at lower SNP concentrations (Fig. 8A), suggesting decreased responsiveness of VSMCs to vasodilators. In comparison, SNP-induced relaxation was not significantly different in the aorta or mesenteric artery of the different groups (Fig. 8B, 8C).

Lung Histology, Morphometric Analysis and Pulmonary Artery Gene Expression Analysis:

In lung tissue sections stained with hematoxylin and eosin, the % wall thickness of the pulmonary arterioles was significantly greater in the Su/Hx group compared to the Nx group (Fig. 9). Real time PCR analysis of Pulmonary Arteries harvested from our experimental animals demonstrated significantly lower levels of a panel of contractile markers in the Su/Hx group compared to the Nx group (Fig. 10). These markers are components of the VSMC contractile apparatus and include alpha smooth muscle actin, calponin, myosin heavy chain, smoothelin and transgelin(also known as SM22a). In contrast there was a trend for increased mRNA of the synthetic or de-differentiation marker for VSMCs retinol binding protein-1 in the Su/Hx compared to the Nx group.

16

DISCUSSION

The major novel findings of our study in the Su/Hx rat model of severe PH are: 1) decreased pulmonary artery contraction in response to Phe and KCl, 2) decreased relaxation of pulmonary artery to ACh and SNP, 3) decreased pulmonary vascular production and responsiveness to the NO-cGMP relaxation pathway, and 4) downregulation of contractile markers in pulmonary arteries. These findings are specific to the pulmonary circulation and are in the context of elevated RVSP, RVH and pulmonary vascular remodeling in this model.

Regulation of pulmonary vascular tone is achieved by the balance between vasoconstrictor and vasodilator stimuli that are responsive to changing physiologic needs. A pathologic shift in this balance is known to contribute to the development of PH in human patients and in preclinical models of the disease (Gillespie et al., 1986; Adnot et al., 1991; Fullerton et al., 1996; Geraci et al., 1999; Shimoda et al., 2000b; Hoshikawa et al., 2001; Ivy et al., 2002; Fagan et al., 2004; Ambalavanan et al., 2005; Schermuly et al., 2005; Homma et al., 2007). This knowledge has formed the basis of all current therapies that either enhance vasodilator mechanisms such as the prostacyclin-cAMP pathway and the NO-cGMP pathway, or inhibit vasoconstrictor mechanisms such as the endothelin and intracellular Ca^{2+} pathways (Lee et al., 2008; Burger, 2009; Stehlik and Movsesian, 2009; Yin et al., 2009). However, altered vascular tone is not always the predominant pathogenetic mechanism since many patients have a "fixed" component in their disease and this, unfortunately, is not optimally responsive to current vasodilator therapies. This "fixed" component is largely due to excessive pulmonary vascular remodeling as a result of altered biology of various cell types at the pulmonary vascular wall. Accumulating evidence in both human and animal studies supports that pulmonary vascular smooth muscle cell phenotypic switch from a contractile to a synthetic and proliferative phenotype is one of the underlying pathogenetic mechanisms in pulmonary hypertension (Michelakis et al., 2002; McMurtry et al., 2004; McMurtry et al., 2005; Bonnet et al., 2007; Li et al., 2009). This raises the exciting possibility for a novel therapeutic strategy

17

aiming to restore a contractile pulmonary VSMC phenotype and reverse structural remodeling which is likely to ameliorate vascular dysfunction and enhance responsiveness to vasodilator therapies.

Since PH is a rare and heterogeneous disease, several animal models have been developed that share many features of the human disease and provided insights into pathogenetic mechanisms. We and others previously studied pulmonary vascular function in the Hx, and monocrotaline (MCT) models of PH and found significant impairments in pulmonary vascular responsiveness along with significant hemodynamic and structural changes in the pulmonary circulation (Christou et al., 2000; Hoshikawa et al., 2003; Schermuly et al., 2004; Arciniegas et al., 2007; Nozik-Grayck and Stenmark, 2007; Majka et al., 2008). These changes were pulmonary vascular bed-specific since we did not find major effects in the systemic circulation. The mechanisms for pulmonary vascular bed specificity in these animal models may relate to differential sensitivity of pulmonary vascular cells due to their baseline physiologic exposure to hypoxia or to differences in the way vascular cells from different beds sense, signal and respond to adverse stimuli. In our prior studies, we found that these changes can be targeted by therapeutic interventions that seem to restore a contractile pulmonary vascular smooth muscle cell phenotype (Christou et al., 2012). The adult rat Su/Hx model of severe PH was described by Taraseviciene-Stewart and coworkers (Taraseviciene-Stewart et al., 2001) and is thought to more closely recapitulate the human condition because of the similarities in pulmonary vascular pathology, its progressive nature, and its ultimate lethality. In this model, despite the systemic administration of Su and the global effects of exposure to hypoxia, the vascular pathology seems to be pulmonary vascular bed- specific. However, the underlying changes in pulmonary vascular function in this model have not been previously studied. Also, the effects on systemic vascular function in the Su/Hx model were not previously described. We thus examined vascular reactivity in pulmonary and systemic vessels to better understand the vascular mechanisms underlying PH in the Su/Hx model.

18

Our hemodynamic measurements confirm that the Su/Hx rat model of PH is characterized by more severe PH than that induced by hypoxia or sugen alone. Consistent with previous reports (de Raaf et al., 2014), the RVSP was greater in Su/Hx compared to Nx, Hx or Su rats. Also, the Fulton's index and the RV/Body weight ratio, as measures of right ventricular hypertrophy, were greater in Su/Hx compared to Nx, Hx and Su rats. These findings are consistent with previous reports that demonstrate that hypoxia-induced pulmonary hypertension is spontaneously reversible upon return to normoxia (de Raaf et al., 2014) and that treatment with sugen alone is inconsistent in producing sustained PH likely because of individual animal variability in susceptibility (Jiang et al., 2015). The combination of Su/Hx produced a robust increase in all components of PH (RVSP, RVH and structural remodeling) and thus support that this is a suitable model to examine the vascular mechanisms underlying severe PH.

We measured the responses to the α-adrenergic receptor agonist Phe, a potent vasoconstrictor (Leblais et al., 2004), and found that pulmonary artery contraction to Phe was markedly reduced in Su/Hx compared to Nx rats. The reduction in Phe contraction of pulmonary artery can not be attributed to Hx alone or Su alone because: 1) The pulmonary artery contraction to Phe was not different in Hx compared to Nx rats. Previous studies have suggested that a hallmark of hypoxic PH is an increase in vasomotor tone (Shimoda et al., 2000a; Oka et al., 2007). For instance, chronic Hx may increase the production/activity of vasoconstrictors such as endothelin-1 (ET-1) and angiotensin II (AngII) in the lung (Shimoda et al., 2000b) or induce direct effects on pulmonary VSMCs, modulating receptor population, ion channel activity, K^+ current, membrane depolarization, elevation in cytosolic Ca^{2+} (Shimoda et al., 2000b) or signal transduction pathways such as Rho kinase (Oka et al., 2007). We have previously shown that Hx treatment for 2 weeks was sufficient to cause decreases in pulmonary artery contraction to Phe (Christou et al., 2012) and this was consistent with another report by Itoh at al in which ET-1-induced vasoconstriction of pulmonary artery strips was reduced in the Hx rat model of PH (Itoh et al., 1999). The difference in the results of the

19

various studies could be due to differences in the vasoconstrictive agonists used (Phe vs. ET-1 or AngII) or the vascular preparation used (pulmonary artery vs. isolated perfused lungs). Also, our previous study was done immediately after two weeks of hypoxic exposure whereas in the current study, we exposed animals to hypoxia for three weeks and allowed them to recover for four weeks in normoxia. Our results are in agreement with previous studies in which hemodynamic changes improve in the hypoxic model after the animals return to normoxia (de Raaf et al., 2014). 2) The pulmonary artery contraction to Phe was slightly increased in Su compared to Nx rats. This is consistent with reports that Su is a potent VEGF receptor antagonist (O'Farrell et al., 2004), and is therefore expected to decrease vascular relaxation and in turn enhance vascular contraction. 3) The pulmonary artery contraction to Phe was significantly reduced in Su/Hx compared to Su alone rats, suggesting that combined Su/Hx was necessary for the induction of the significant pulmonary pathology. 4) The changes in Phe contraction appear to be specific to the pulmonary artery, as the Phe contraction in other systemic arteries such as the aorta and mesenteric artery was not different among the different groups of rats.

The interaction of Phe with α-adrenergic receptors is coupled to activation of GTP-binding protein and various Ca^{2+}-dependent and Ca^{2+}-independent mechanisms of VSM contraction (Dallas and Khalil, 2003). The observed decrease in Phe contraction of pulmonary artery may be partly due to changes in the sensitivity of α-adrenergic receptors or affinity to Phe because the Phe ED_{50} was reduced in Su/Hx compared to Nx, Hx and Su rats. Also, the contraction of pulmonary artery to membrane depolarization by high KCl, a receptor-independent response that involves stimulation of Ca^{2+} entry through voltage gated channels (Murphy et al., 2001; Mazzuca et al., 2015), was reduced in Su/Hx compared to Nx rats, suggesting that the reduced pulmonary vascular response could be partly due to decreased Ca^{2+} entry mechanisms into VSMCs or other post-receptor mechanisms of VSMC contraction, and these possibilities should be verified by measuring cytosolic Ca^{2+} concentration and other contraction mechanisms in pulmonary arterial smooth muscle cells in future experiments. Interestingly,

when the Phe response was measured as % of control KCl contraction, the Phe response was still reduced in Su/Hx compared with Nx, Hx, and Su rats. These observations suggest other mechanisms that could reduce contraction in pulmonary VSMCs of the Su/Hx model of PH. High KCl depolarizing solution affects the K^+ gradient across the plasma membrane, and is therefore expected to affect the outward movement of K^+ ion and the activity of K channels. Different types of K^+ channels have been described in VSMCs, and whether the activity of K^+ channels is altered in Su/Hx model remains to be examined. Our gene expression analysis in isolated pulmonary arteries from Su/Hx animals supports that there is a pattern of de-differentiation as assessed by decreased abundance of five contractile markers. This finding is in agreement with prior studies that reported evidence of VSMC de-differentiation in other models of PH as well as human PAH (Li et al., 2009; Xiao et al., 2013). Future studies should examine if the changes in mRNA expression of contractile markers translate into changes in protein levels using Western blot analysis.

We examined whether the impaired pulmonary vasoconstriction in Su/Hx rats could be attributed to enhanced release of endothelium-derived relaxing factor (EDRF). The endothelium is known to release nitric oxide (NO) (Busse and Fleming, 1999) prostacyclin (Parkington et al., 2004) and endothelium-derived hyperpolarizing factors (EDHF) (Feletou and Vanhoutte, 2006). NO is known to diffuse into VSMCs where it activates guanylate cyclase and increase cGMP. cGMP in turn would promote relaxation by decreasing intracellular Ca^{2+} or reducing the Ca^{2+} sensitivity of the contractile proteins. Our ACh experiments in Nx rats demonstrate an intact endothelium-dependent relaxation of pulmonary artery that is abolished by endothelium removal. Also, the observations that the NOS inhibitor L-NAME and guanylate cyclase inhibitor ODQ blocked ACh relaxation in the pulmonary artery suggest a role of the NO-cGMP relaxation pathway. The NO-cGMP pathway appears to be impaired in the pulmonary artery of Su/Hx rats. This is supported by the following findings: 1) ACh-induced relaxation was not different from Nx rats in pulmonary artery of Hx rats, partially reduced in Su rats, and significantly reduced in Su/Hx rats compared to Nx and Hx rats. 2) The reduction in

ACh relaxation in Su/Hx rats compared to other groups was specific to the pulmonary artery and not observed in the aorta or mesenteric artery. 3) Blockade of NO production by L-NAME enhanced Phe contraction as % of KCl in Nx rats but not Hx, Su and Su/Hx rats, suggesting that the NO pathway is intact in Nx rats but impaired in Hx, Su and Su/Hx rats. 4) NO production was reduced in pulmonary artery of Su/Hx compared to Nx rats, and the reduction was not observed in the aorta or mesenteric artery.

Other alterations in the NO-cGMP pathway were also observed among the different groups of rats. NO production was significantly reduced in pulmonary artery of Su alone rats. This is consistent with the observed decrease in ACh relaxation in Su alone rats and could be related to Su-induced blockade of the effects of VEGF and resulting endothelial cell dysfunction. Also, NO production was reduced in pulmonary artery of Hx compared to Nx rats, although ACh relaxation was not different between the two groups. This is likely because ACh relaxation may also involve other pathways such as PGI_2 and EDHF (Majed and Khalil, 2012; Mazzuca et al., 2015) and these pathways may still be functional in the Hx rats and should be examined in future studies. Also, despite the marked decrease in NO production which is expected to cause a decrease in guanylate cyclase activity, ODQ caused significant enhancement of Phe contraction as % of KCl in Su alone and Su/Hx rats. This could be partly explained by possible compensatory increase in guanylate cyclase activity to rescue against the marked decrease in NO in the Su and Su/Hx rats. Although we did not directly measure Ca^{2+} sensitivity, assuming that KCl contraction is mainly due to Ca^{2+} influx (Murphy and Khalil, 2000) then the enhanced Phe contraction as a percentage of KCl contraction in ODQ treated guanylate cyclase-blocked pulmonary artery of Su and Su/Hx rats is likely due to activation of Ca^{2+}-sensitization pathways such as protein kinase C or Rho-kinase (Weigand et al., 2011) and the contribution of these pathways to pulmonary artery contraction in the Su/Hx animal models of PH should be further examined. The changes in Ca^{2+} sensitization pathways were not observed in control non treated vessels because they were likely obscured by compensatory increased guanylate cyclase activity, and only with blockade of guanylate

cyclase the enhanced contraction mechanisms could be manifested. This is supported by reports that cGMP reduces $[Ca^{2+}]_i$ (Lincoln et al., 1990), and cGMP-dependent protein kinase causes phosphorylation and inhibition of myosin light chain kinase and Ca^{2+} sensitization pathways (Salamanca and Khalil, 2005). Interestingly, Rho kinase has been suggested to play a role in PH, and Rho kinase inhibitors have been effective as potential therapies in experimental PH (Oka et al., 2008) Whether the changes in the Ca^{2+} sensitization mechanisms of VSM contraction are directly caused by Hx, Su or both is unclear and needs to be further examined.

SNP is an exogenous NO donor that causes direct stimulation of guanylate cyclase and increases in cGMP levels. In the present study, SNP-induced pulmonary artery relaxation was not different in pulmonary artery of Hx or Su alone rats, but was significantly reduced in Su/Hx rats. Also, the reduction in SNP relaxation in Su/Hx rats was specific to the pulmonary artery and not observed in the aorta and mesenteric artery. These observations suggest that in addition to the reduced NO production, the reduced pulmonary artery relaxation to SNP in Su/Hx rats may be related to structural changes in the pulmonary vascular wall that lead to decreased responsiveness of pulmonary VSMCs to vasodilators. Previous studies have shown that ACh-induced relaxation in isolated perfused lung preparations is reduced in rats exposed to Hx for 1 week and abolished after 3 weeks Hx exposure (Adnot et al., 1991). Other studies have shown enhanced pressor response to ET-1 in Hx rats compared to controls with no potentiation of the pressor response by EDRF antagonists (hydroquinone, methylene blue, and pyrogallol). However, the endothelium-independent vasodilation by SNP was fully active in Hx rats and it was concluded that Hx-induced PH is associated with a loss of EDRF activity in pulmonary vessels (Adnot et al., 1991). On the other hand, our observation that both ACh- and SNP-induced relaxation are reduced in pulmonary arteries of Su/Hx rats is similar to the findings in the MCT model of progressive lung injury and PH where both endothelial-dependent and endothelial-independent relaxation were reduced (Fullerton et al., 1996). Taken together, these observations suggest that the decreased ACh- and SNP-induced

relaxation in pulmonary artery of Su/Hx rats are due to reduced NO production as well as structural changes in the pulmonary vascular wall that lead to decreased responsiveness of pulmonary VSMCs to vasodilators. Other potential factors that could contribute to the observed decreased responsiveness to SNP in the Su/Hx model may include increased phosphodiesterase-5 (PDE5) activity or decreased protein kinase G activity and this should be examined in future studies. A prior report showed that maximal ACh-induced relaxation was reduced in extralobar first-branch pulmonary artery rings of Su/Hx model in Fischer 344 rats (Alzoubi et al., 2013). While the present study also showed impaired ACh relaxation in extralobar pulmonary artery rings, it was conducted in a Su/Hx model in a different strain of rats (Sprague-Dawley). Also, our study provided more in depth analysis of the ACh concentration-response curve, the endothelium-dependent ACh response vs endothelium-independent SNP response, and more mechanistic information regarding the role of NO-cGMP pathway and the sensitivity of this pathway to inhibitors of NOS and guanylate cyclase (L-NAME and ODQ) and endothelium-removal, as well as direct measurements of nitric oxide metabolites. Furthermore the present study showed that the reduced endothelium-dependent and endothelium-independent relaxation pathways were specific to the pulmonary artery of Su/Hx rats and were not observed in the aorta or mesenteric artery. Thus the present study demonstrates impaired endothelium-dependent as well as endothelium-independent pulmonary artery relaxation. It would be important to test whether infusion of vasodilators in Su/Hx model *in vivo* affects pulmonary arterial pressure. Interestingly, a recent study demonstrated that acute IV infusion of the vasodilator agent adenosine caused a dose-dependent reduction in pulmonary artery pressure in anesthetized Wistar rats with Su/Hx-induced PH (Iglarz et al., 2015), suggesting that at an earlier five week time point, there is a reactive component of PH in this rat strain. Whether this reactive component of PH to vasodilators could still be observed at a later seven week time point and in the Sprague-Dawley rat model of Su.Hx remains to be investigated.

PH is associated with remodeling of the small pulmonary arteries, vascular cell proliferation and obliteration of the pulmonary microvasculature (Pietra et al., 1989; Mitani et

al., 2001; Budhiraja et al., 2004; Farber and Loscalzo, 2004). Some studies have shown that chronic Hx is associated with increased proliferation and migration of VSMCs and a synthetic pulmonary VSMC phenotype (Cooper and Beasley, 1999; Schultz et al., 2006; Chen and Khalil, 2008). The "proliferative" or "synthetic" VSMCs lose their ability to contract, partly due to lack of contractile proteins like myosin. Our data support potential VSMC phenotypic switch from a contractile to the synthetic phenotype in Su/Hx rats because: 1) Both Phe and KCl contraction, were reduced in pulmonary artery of Su/Hx rats compared with Nx, Hx and Su rats. 2) The vasodilator responses of pulmonary artery to both ACh and SNP were reduced in Su/Hx compared with Nx and Hx rats. 3) Even after endothelium removal, the KCl contraction was still reduced in Su/Hx compared to Nx and Su rats. 4) Histological analysis demonstrated increased thickening of pulmonary arteriolar wall thickening in Su/Hx compared to Nx rats. 5) Contractile markers were reduced in the pulmonary arteries of Su/Hx compared to Nx rats. A prior study showed that the contraction to only one concentration of Phe (10^{-6} M) and KCl (80 mm) was insignificantly enhanced in pulmonary artery of Su/HX model in Fischer 344 rats (Alzoubi et al., 2013). This is different from the present findings that both Phe and KCl contraction were significantly reduced in our Su/Hx model. The difference in the results could be related to differences in the rat strain (Sprague-Dawley vs Fischer 344). Also, the present study examined the full concentration-response curve to Phe rather than the response to only one Phe concentration, thus demonstrating decreased sensitivity particularly to low Phe concentrations in the pulmonary artery of Su/Hx rats. Additionally, the present study examined how the contractile response to Phe could be modified by inhibitors of the NO-cGMP relaxation pathway and endothelium removal. Most importantly, the present study showed that the reduced Phe and KCl contraction were specific to the pulmonary artery of Su/Hx rats and were not observed in the aorta or mesenteric artery. The differences in the findings make it important to further study the changes in vascular function in other Su/Hx models in future studies. Nevertheless, the present study is the first to describe in a comprehensive manner the full spectrum of vascular dysfunction in Su/Hx Sprague-Dawley rats which extends beyond endothelial dysfunction. Our observed decrease in

mechanical force to vasoconstrictor stimuli and decreased relaxation to vasodilator stimuli is a novel finding and supports structural remodelling and stiffening of the pulmonary vascular wall. Our findings suggest that in addition to endothelial dysfunction, there is impaired intrinsic VSMC dysfunction and thus provide a novel target for potential therapies.

One limitation of the present study is that we used extra-lobar first branch pulmonary arteries which may not reflect the entire pulmonary circulation particularly the intralobar resistance vessels that are thought to play a greater role in the control of pulmonary vascular resistance. Future studies should examine whether the observed reduced contraction/relaxation in extra-lobar pulmonary arteries also occur in distal intralobar resistance vessels. However, studies in more proximal vessels are also important for the following reasons: 1. Small intralobular arteries take their vascular feed from the larger extralobar conduit pulmonary arteries, and remodeling of the parent conduit arteries are expected to affect the structural integrity and function of the smaller branches and downstream vessels. 2. Thickening of the tunica media occurs at all levels of the arterial tree in the context of pulmonary vascular remodeling (Pugliese et al., 2015). 3. Some authors have reported qualitative similarities (and quantitative difference) in vasoactive responses between main and intralobar pulmonary arteries in the setting of experimental Pulmonary Hypertension (Jeffery and Wanstall, 2001), and 4. Functional changes in pulmonary vascular stiffness are increasingly thought to be important in disease progression and were shown to be mainly due to decreased compliance of larger vessels (Hunter et al., 2011). Given that there is increasing appreciation of the contribution of proximal vascular stiffness to pulmonary vascular impedance in the setting of PH (Lammers et al., 2008; Sanz et al., 2009) we believe it is important to examine these responses in addition to the changes in the distal pulmonary circulation in experimental PH. Nevertheless, the vasorelaxation effects may depend not only on the size of the vessel but also on the vasodilator factors involved. While NO plays a greater role in larger vessels, EDHF is more important in smaller vessels. There is a possibility that a smaller pulmonary artery might show differences in vasorelaxation compared with the first

branch, and therefore the vasorelaxation response in smaller branches are important and should be examined in future investigations.

The present study focused on understanding the mechanisms underlying impaired pulmonary vascular contractility in the Su/Hx model with the hope that improved understanding of these mechanisms will provide the framework for future intervention studies to evaluate the efficacy of novel agents aiming to restore a contractile pulmonary VSMC phenotype. In this context, we found that endothelium-dependent relaxation was reduced in Su/Hx model of PH. Endothelium-derived vasodilators include NO, PGI_2 and EDHF. We observed that ACh-induced relaxation of pulmonary artery was completely abolished by the NOS inhibitor L-NAME and guanylate cyclase inhibitor ODQ, suggesting a major role of NO-cGMP pathway, and likely a minimal role of PGI_2 or EDHF. While our studies suggest a relatively small role of endothelium-derived PGI_2 in the observed changes in pulmonary artery of Su/Hx, this does not exclude the possibility of PGI_2 release from other vascular cells including VSMCs. Given the favorable vascular effects of PGI_2 therapy in the management of PH, future studies should further examine the levels of PGI_2 and the blood pressure depressor and vasodilator responsiveness to PGI_2 in the Su/Hx model of PH.

Perspective

Studies in animal models of PH provide important information regarding the vascular and molecular mechanisms underlying human PH. The present study demonstrates that severe PH in the Su/Hx model is associated with reduced responsiveness of the pulmonary arterial circulation to both vasoconstrictor and vasodilator stimuli. The specific reduction in the pulmonary vascular responses in the setting of Su/Hx-induced PH may be explained by a vascular bed-specific switch of VSMCs from a contractile to a synthetic phenotype, as well as reduction in endothelium-dependent relaxation pathways. Our results may have important clinical implications for PH as they suggest that therapeutic interventions targeting

vasoconstriction may not produce the desired effects unless new approaches to improve the

responsiveness of the pulmonary circulation to vasoactive substances are developed.

ACKNOWLEDGEMENTS

Authorship Contributions

Participated in research design: Christou, Hudalla, Michael, Filatava, Khalil. *Conducted experiments*: Christou, Hudalla, Michael, Filatava, Li, Zhu, Possomato-Vieira, Dias-Junior. *Performed data analysis*: Christou, Hudalla, Michael, Filatava, Li, Zhu, Possomato-Vieira, Dias-Junior, Khalil. *Wrote or contributed to the writing of the manuscript*: Christou, Hudalla, Michael, Kourembanas, Khalil.

References

Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF and Oka M (2010) Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. *Circulation* **121**:2747-2754.

Adnot S, Raffestin B, Eddahibi S, Braquet P and Chabrier PE (1991) Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. *J Clin Invest* **87**:155-162.

Aiello RJ, Bourassa PA, Zhang Q, Dubins J, Goldberg DR, De Lombaert S, Humbert M, Guignabert C, Cavasin MA, McKinsey TA and Paralkar V (2017) Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension. *J Pharmacol Exp Ther* **360**:267-279.

Alzoubi A, Almalouf P, Toba M, O'Neill K, Qian X, Francis M, Taylor MS, Alexeyev M, McMurtry IF, Oka M and Stevens T (2013) TRPC4 inactivation confers a survival benefit in severe pulmonary arterial hypertension. *Am J Pathol* **183**:1779-1788.

Ambalavanan N, Bulger A, Murphy-Ullrich J, Oparil S and Chen YF (2005) Endothelin-A receptor blockade prevents and partially reverses neonatal hypoxic pulmonary vascular remodeling. *Pediatr Res* **57**:631-636.

Arciniegas E, Frid MG, Douglas IS and Stenmark KR (2007) Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. *Am J Physiol Lung Cell Mol Physiol* **293**:L1-8.

Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, Hashimoto K, Bonnet SN and Michelakis ED (2007) The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. *Proc Natl Acad Sci U S A* **104**:11418-11423.

Budhiraja R, Tuder RM and Hassoun PM (2004) Endothelial dysfunction in pulmonary hypertension. *Circulation* **109**:159-165.

Burger CD (2009) Pulmonary hypertension in COPD: a review and consideration of the role of arterial vasodilators. *COPD* **6**:137-144.

Busse R and Fleming I (1999) Nitric oxide, nitric oxide synthase, and hypertensive vascular disease. *Curr Hypertens Rep* **1**:88-95.

Chen W and Khalil RA (2008) Differential [Ca2+]i signaling of vasoconstriction in mesenteric microvessels of normal and reduced uterine perfusion pregnant rats. *Am J Physiol Regul Integr Comp Physiol* **295**:R1962-1972.

Christou H, Morita T, Hsieh CM, Koike H, Arkonac B, Perrella MA and Kourembanas S (2000) Prevention of hypoxia-induced pulmonary hypertension by enhancement of endogenous heme oxygenase-1 in the rat. *Circ Res* **86**:1224-1229.

Christou H, Reslan O, Mam V, Tanbe AF, Vitali SH, Touma M, Arons E, Mitsialis SA, Kourembanas S and Khalil RA (2012) Improved Pulmonary Vascular Reactivity and Decreased Hypertrophic Remodeling during Non-Hypercapnic Acidosis in Experimental Pulmonary Hypertension. *American Journal of Physiology-Lung Cellular and Molecular Physiol* **In press**.

Cooper AL and Beasley D (1999) Hypoxia stimulates proliferation and interleukin-1alpha production in human vascular smooth muscle cells. *Am J Physiol* **277**:H1326-1337.

Crews JK, Herrington JN, Granger JP and Khalil RA (2000) Decreased endothelium-dependent vascular relaxation during reduction of uterine perfusion pressure in pregnant rat. *Hypertension* **35**:367-372.

Dallas A and Khalil RA (2003) Ca2+ antagonist-insensitive coronary smooth muscle contraction involves activation of epsilon-protein kinase C-dependent pathway. *Am J Physiol Cell Physiol* **285**:C1454-1463.

de Raaf MA, Schalij I, Gomez-Arroyo J, Rol N, Happe C, de Man FS, Vonk-Noordegraaf A, Westerhof N, Voelkel NF and Bogaard HJ (2014) SuHx rat model: partly reversible pulmonary hypertension and progressive intima obstruction. *Eur Respir J* **44**:160-168.

Fagan KA, Oka M, Bauer NR, Gebb SA, Ivy DD, Morris KG and McMurtry IF (2004) Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. *Am J Physiol Lung Cell Mol Physiol* **287**:L656-664.

Farber HW and Loscalzo J (2004) Pulmonary arterial hypertension. *N Engl J Med* **351**:1655-1665.

Feletou M and Vanhoutte PM (2006) Endothelium-derived hyperpolarizing factor: where are we now? *Arterioscler Thromb Vasc Biol* **26**:1215-1225.

Fullerton DA, Hahn AR and McIntyre RC, Jr. (1996) Mechanistic imbalance of pulmonary vasomotor control in progressive lung injury. *Surgery* **119**:98-103.

Geraci MW, Gao B, Shepherd DC, Moore MD, Westcott JY, Fagan KA, Alger LA, Tuder RM and Voelkel NF (1999) Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. *J Clin Invest* **103**:1509-1515.

Gillespie MN, Olson JW, Reinsel CN, O'Connor WN and Altiere RJ (1986) Vascular hyperresponsiveness in perfused lungs from monocrotaline-treated rats. *Am J Physiol* **251**:H109-114.

Homma N, Nagaoka T, Morio Y, Ota H, Gebb SA, Karoor V, McMurtry IF and Oka M (2007) Endothelin-1 and serotonin are involved in activation of RhoA/Rho kinase signaling in the chronically hypoxic hypertensive rat pulmonary circulation. *J Cardiovasc Pharmacol* **50**:697-702.

Hoshikawa Y, Nana-Sinkam P, Moore MD, Sotto-Santiago S, Phang T, Keith RL, Morris KG, Kondo T, Tuder RM, Voelkel NF and Geraci MW (2003) Hypoxia induces different genes in the lungs of rats compared with mice. *Physiol Genomics* **12**:209-219.

Hoshikawa Y, Voelkel NF, Gesell TL, Moore MD, Morris KG, Alger LA, Narumiya S and Geraci MW (2001) Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. *Am J Respir Crit Care Med* **164**:314-318.

Hunter KS, Lammers SR and Shandas R (2011) Pulmonary vascular stiffness: measurement, modeling, and implications in normal and hypertensive pulmonary circulations. *Compr Physiol* **1**:1413-1435.

Iglarz M, Landskroner K, Bauer Y, Vercauteren M, Rey M, Renault B, Studer R, Vezzali E, Freti D, Hadana H, Schlapfer M, Cattaneo C, Bortolamiol C, Weber E, Whitby BR, Delahaye S, Wanner D, Steiner P, Nayler O, Hess P and Clozel M (2015) Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension. *J Cardiovasc Pharmacol* **66**:457-467.

Itoh H, Yokochi A, Yamauchi-Kohno R and Maruyama K (1999) Effects of the endothelin ET(A) receptor antagonist, TA-0201, on pulmonary arteries isolated from hypoxic rats. *Eur J Pharmacol* **376**:233-238.

Ivy DD, Yanagisawa M, Gariepy CE, Gebb SA, Colvin KL and McMurtry IF (2002) Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats. *Am J Physiol Lung Cell Mol Physiol* **282**:L703-712.

Jeffery TK and Wanstall JC (2001) Comparison of pulmonary vascular function and structure in early and established hypoxic pulmonary hypertension in rats. *Can J Physiol Pharmacol* **79**:227-237.

Jiang B, Deng Y, Suen C, Taha M, Chaudhary KR, Courtman DW and Stewart DJ (2015) Marked Strain-specific Differences in the SU5416 Rat Model of Severe Pulmonary Arterial Hypertension. *Am J Respir Cell Mol Biol*.

Lammers SR, Kao PH, Qi HJ, Hunter K, Lanning C, Albietz J, Hofmeister S, Mecham R, Stenmark KR and Shandas R (2008) Changes in the structure-function relationship of elastin and its impact on the proximal pulmonary arterial mechanics of hypertensive calves. *Am J Physiol Heart Circ Physiol* **295**:H1451-1459.

Leblais V, Pourageaud F, Ivorra MD, Guibert C, Marthan R and Muller B (2004) Role of alpha-adrenergic receptors in the effect of the beta-adrenergic receptor ligands, CGP 12177, bupranolol, and SR 59230A, on the contraction of rat intrapulmonary artery. *J Pharmacol Exp Ther* **309**:137-145.

Lee JE, Hillier SC and Knoderer CA (2008) Use of sildenafil to facilitate weaning from inhaled nitric oxide in children with pulmonary hypertension following surgery for congenital heart disease. *J Intensive Care Med* **23**:329-334.

Li X, Zhang X, Leathers R, Makino A, Huang C, Parsa P, Macias J, Yuan JX, Jamieson SW and Thistlethwaite PA (2009) Notch3 signaling promotes the development of pulmonary arterial hypertension. *Nat Med* **15**:1289-1297.

Lincoln TM, Cornwell TL and Taylor AE (1990) cGMP-dependent protein kinase mediates the reduction of Ca2+ by cAMP in vascular smooth muscle cells. *Am J Physiol* **258**:C399-407.

Majed BH and Khalil RA (2012) Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. *Pharmacol Rev* **64**:540-582.

Majka SM, Skokan M, Wheeler L, Harral J, Gladson S, Burnham E, Loyd JE, Stenmark KR, Varella-Garcia M and West J (2008) Evidence for cell fusion is absent in vascular lesions associated with pulmonary arterial hypertension. *Am J Physiol Lung Cell Mol Physiol* **295**:L1028-1039.

Mam V, Tanbe AF, Vitali SH, Arons E, Christou HA and Khalil RA (2010) Impaired vasoconstriction and nitric oxide-mediated relaxation in pulmonary arteries of hypoxia- and monocrotaline-induced pulmonary hypertensive rats. *J Pharmacol Exp Ther* **332**:455-462.

Mazzuca MQ, Li W, Reslan OM, Yu P, Mata KM and Khalil RA (2014) Downregulation of microvascular endothelial type B endothelin receptor is a central vascular mechanism in hypertensive pregnancy. *Hypertension* **64**:632-643.

Mazzuca MQ, Mata KM, Li W, Rangan SS and Khalil RA (2015) Estrogen receptor subtypes mediate distinct microvascular dilation and reduction in [Ca2+]I in mesenteric microvessels of female rat. *J Pharmacol Exp Ther* **352**:291-304.

McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, Bonnet S, Puttagunta L and Michelakis ED (2005) Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. *J Clin Invest* **115**:1479-1491.

McMurtry MS, Bonnet S, Wu X, Dyck JR, Haromy A, Hashimoto K and Michelakis ED (2004) Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. *Circ Res* **95**:830-840.

Michelakis ED, Wu X, McMurtry MS, Dyck JR, Moudgil R, Hopkins TA, Lopaschuk GD, Puttagunta L, Waite R and Archer SL (2002) Dichloroacetate, a metabolic Modulator, Prevents and Reverses Chronic Hypoxic Pulmonary Hypertension in Rats. Role of Increased Expression and Activity of Voltage-Gated Potassium Channels. . *Circ* **105**:244-250.

Mitani Y, Ueda M, Komatsu R, Maruyama K, Nagai R, Matsumura M and Sakurai M (2001) Vascular smooth muscle cell phenotypes in primary pulmonary hypertension. *Eur Respir J* **17**:316-320.

Murphy JG, Fleming JB, Cockrell KL, Granger JP and Khalil RA (2001) [Ca(2+)](i) signaling in renal arterial smooth muscle cells of pregnant rat is enhanced during inhibition of NOS. *Am J Physiol Regul Integr Comp Physiol* **280**:R87-99.

Murphy JG and Khalil RA (2000) Gender-specific reduction in contractility and [Ca(2+)](i) in vascular smooth muscle cells of female rat. *Am J Physiol Cell Physiol* **278**:C834-844.

Nozik-Grayck E and Stenmark KR (2007) Role of reactive oxygen species in chronic hypoxia-induced pulmonary hypertension and vascular remodeling. *Adv Exp Med Biol* **618**:101-112.

O'Farrell AM, Yuen HA, Smolich B, Hannah AL, Louie SG, Hong W, Stopeck AT, Silverman LR, Lancet JE, Karp JE, Albitar M, Cherrington JM and Giles FJ (2004) Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. *Leuk Res* **28**:679-689.

Oka M, Fagan KA, Jones PL and McMurtry IF (2008) Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. *Br J Pharmacol* **155**:444-454.

Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, Voelkel NF and McMurtry IF (2007) Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. *Circ Res* **100**:923-929.

Parkington HC, Coleman HA and Tare M (2004) Prostacyclin and endothelium-dependent hyperpolarization. *Pharmacol Res* **49**:509-514.

Pietra GG, Edwards WD, Kay JM, Rich S, Kernis J, Schloo B, Ayres SM, Bergofsky EH, Brundage BH, Detre KM and et al. (1989) Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. *Circulation* **80**:1198-1206.

Pugliese SC, Poth JM, Fini MA, Olschewski A, El Kasmi KC and Stenmark KR (2015) The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes. *Am J Physiol Lung Cell Mol Physiol* **308**:L229-252.

Ringvold HC and Khalil RA (2017) Protein Kinase C as Regulator of Vascular Smooth Muscle Function and Potential Target in Vascular Disorders. *Advances in Pharmacology* **78**:203-301.

Salamanca DA and Khalil RA (2005) Protein kinase C isoforms as specific targets for modulation of vascular smooth muscle function in hypertension. *Biochem Pharmacol* **70**:1537-1547.

Sanz J, Kariisa M, Dellegrottaglie S, Prat-Gonzalez S, Garcia MJ, Fuster V and Rajagopalan S (2009) Evaluation of pulmonary artery stiffness in pulmonary hypertension with cardiac magnetic resonance. *JACC Cardiovasc Imaging* **2**:286-295.

Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W and Grimminger F (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. *J Clin Invest* **115**:2811-2821.

Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermert L, Ermert M, Weissmann N, Rose F, Guenther A, Walmrath D, Seeger W and Grimminger F (2004) Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. *Am J Respir Crit Care Med* **169**:39-45.

Schultz K, Fanburg BL and Beasley D (2006) Hypoxia and hypoxia-inducible factor-1alpha promote growth factor-induced proliferation of human vascular smooth muscle cells. *Am J Physiol Heart Circ Physiol* **290**:H2528-2534.

Shimoda LA, Sham JS, Shimoda TH and Sylvester JT (2000a) L-type Ca(2+) channels, resting [Ca(2+)](i), and ET-1-induced responses in chronically hypoxic pulmonary myocytes. *Am J Physiol Lung Cell Mol Physiol* **279**:L884-894.

Shimoda LA, Sham JS and Sylvester JT (2000b) Altered pulmonary vasoreactivity in the chronically hypoxic lung. *Physiol Res* **49**:549-560.

Stehlik J and Movsesian MA (2009) Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure. *J Card Fail* **15**:31-34.

Stenmark KR, Meyrick B, Galie N, Mooi WJ and McMurtry IF (2009) Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. *Am J Physiol Lung Cell Mol Physiol* **297**:L1013-1032.

Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, Voelkel NF and Tuder RM (2001) Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. *Faseb J* **15**:427-438.

Tonelli AR, Alnuaimat H and Mubarak K (2010) Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. *Respir Med* **104**:481-496.

Weigand L, Shimoda LA and Sylvester JT (2011) Enhancement of myofilament calcium sensitivity by acute hypoxia in rat distal pulmonary arteries. *Am J Physiol Lung Cell Mol Physiol* **301**:L380-387.

Xiao Y, Christou H, Liu L, Visner G, Mitsialis SA, Kourembanas S and Liu H (2013) Endothelial indoleamine 2,3-dioxygenase protects against development of pulmonary hypertension. *Am J Respir Crit Care Med* **188**:482-491.

Yin N, Kaestle S, Yin J, Hentschel T, Pries AR, Kuppe H and Kuebler WM (2009) Inhaled nitric oxide versus aerosolized iloprost for the treatment of pulmonary hypertension with left heart disease. *Crit Care Med* **37**:980-986.

Zhou C, Townsley MI, Alexeyev M, Voelkel NF and Stevens T (2016) Endothelial hyperpermeability in severe pulmonary arterial hypertension: role of store-operated calcium entry. *Am J Physiol Lung Cell Mol Physiol* **311**:L560-569.

Footnotes

Legends for Figures

Fig. 1. Hemodynamic changes and right ventricular hypertrophy in the Sugen 5416/hypoxia (Su/Hx) model of Pulmonary Hypertension (PH). Schematic representation of experimental timeline (A). Animals were injected with Sugen (20mg/kg s.c.) or vehicle and either exposed to 3 weeks of hypoxia (9% O_2) followed by 4 weeks of normoxia (21% O_2) (Su/Hx and Hx) or kept in normoxia for 7 weeks (Nx, Su). Right ventricular systolic pressure (RVSP) (B), left ventricular systolic pressures (LVSP) (C), Right ventricular hypertrophy (RVH) assessed as the weight of the right ventricle divided by the left ventricle and septum (Fulton's Index, FI; D) or as the ratio of right ventricular weight to body weight (E). Data represent means±SEM, n= 7-17 rats. *P< 0.05.

Fig. 2. KCl-induced contraction in blood vessels of normoxia (Nx), hypoxia (Hx), sugen (SU) and sugen+hypoxia (Su/Hx) rats. Pulmonary artery, aortic, and mesenteric artery rings from Nx, Hx, Su, and Su/Hx rats were either intact (+Endo, A, B, C) or endothelium-denuded (-Endo, D, E, F). The vascular rings were stimulated with KCl (96 mM) and the contraction in gram/mg tissue weight was recorded. Data represent means±SEM, n= 7-11. *P<0.05 vs Nx. #P<0.05 vs Su.

Fig. 3. Phe-induced contraction in blood vessels of normoxia (Nx), hypoxia (Hx), sugen (Su) and sugen+hypoxia (Su/Hx) rats. Pulmonary artery, aortic, and mesenteric artery rings from Nx, Hx, Su, and Su/Hx rats were stimulated with increasing concentrations of Phe (10^{-9} to 10^{-5} M), the contractile response was measured and presented in gram/mg tissue (A, B, C), as % of maximum Phe contraction (D, E, F), or as % of KCl contraction (G, H, I). Data represent means±SEM, n=7-11. *P<0.05 vs Nx. †P<0.05 vs Hx. #P<0.05 vs Su.

Fig. 4. Effect of endothelium removal or blockade of NO-cGMP pathway on Phe-induced contraction of pulmonary artery. Isolated pulmonary artery rings from normoxia (Nx), hypoxia (Hx), sugen (Su) and sugen+hypoxia (Su/Hx) rats were either kept endothelium-intact (open circles), pretreated with the NOS inhibitor L-NAME (3×10^{-4} M) (closed circles) or the guanylate cyclase inhibitor ODQ (10^{-5} M) (open triangles) for 15 min, or endothelium-denuded (closed triangles). The vessels were stimulated with increasing concentrations of Phe, and the contractile response was presented in grams/mg of tissue (A, B, C, D), as % of maximum Phe contraction (E, F, G, H), or as % of control 96 mM KCl contraction (I, J, K, L). Data represent means±SEM, n=7-11. *P<0.05, L-NAME treated vs. control non-treated vessels. [#] P<0.05, ODQ-treated vs. control non-treated vessels.

Fig. 5. ACh-induced relaxation in blood vessels of normoxia (Nx), hypoxia (Hx), sugen (Su) and sugen+hypoxia (Su/Hx) rats. Pulmonary artery (A), aortic (B), and mesenteric artery rings (C) from Nx, Hx, Su, and Su/Hx rats were stimulated with submaximal concentration of Phe, then stimulated with ACh (10^{-9}-10^{-5} M) and the % relaxation of Phe contraction was measured. Data represent means±SEM, n=7-11. *P<0.05 vs Nx. [†]P<0.05 vs Hx.

Fig. 6. Effect of endothelium removal or blockade of NO-cGMP pathway on ACh-induced relaxation of pulmonary artery. Isolated pulmonary artery rings from normoxia (Nx), hypoxia (Hx), sugen (Su) and sugen+hypoxia (Su/Hx) rats were either kept endothelium-intact (open circles), pretreated with the NOS inhibitor L-NAME (3×10^{-4} M) (closed circles) or the guanylate cyclase inhibitor ODQ (10^{-5} M) (open triangles) for 15 min, or endothelium-denuded (closed triangles). The vessels were stimulated with submaximal concentration of Phe, then stimulated with ACh (10^{-9}-10^{-5} M) and the % relaxation of Phe contraction was measured. Data represent means±SEM, n=7-11. * P<0.05, vessels treated with L-NAME or ODQ or endothelium denuded vs. control non-treated endothelium-intact vessels.

Fig. 7. NO production in blood vessels of normoxia (Nx), hypoxia (Hx), sugen (Su) and sugen+hypoxia (Su/Hx) rats. Pulmonary artery (A), aortic (B), and mesenteric artery rings (C) from Nx, Hx, Su, and Su/Hx rats were stimulated with increasing concentrations of ACh and nitrate/nitrite (NOx) production was measured. Data represent means±SEM, n=7-11. *P<0.05 vs Nx.

Fig. 8. SNP-induced relaxation in blood vessels of normoxia (Nx), hypoxia (Hx), sugen (Su) and sugen+hypoxia (Su/Hx) rats. Endothelium-denuded pulmonary artery (A), aortic (B), and mesenteric artery rings (C) from Nx, Hx, Su, and Su/Hx rats were precontracted with submaximal concentration of Phe, then stimulated with SNP (10^{-9}-10^{-5} M) and the % relaxation of Phe contraction was measured. Data represent means±SEM, n=7-11. *P<0.05 vs Nx. †P<0.05 vs Hx. $^{\#}$P<0.05 vs Su.

Fig. 9. Pulmonary vascular remodeling in the Su/Hx-model of pulmonary hypertension. Representative H&E stained peripheral lung sections from each experimental group (Nx, A; Su/Hx, B). Pulmonary arterioles are indicated with arrowheads. Scale bar=50μm. Quantitative morphometric analysis of percentage wall thickness of pulmonary arterioles defined as the area occupied by the vessel wall divided by the total cross sectional area of the arteriole (C). Graph bars represent means±SEM of 30-52 vessels from 5 rats per group. *P< 0.05.

Fig. 10. Pulmonary artery smooth muscle cell de-differentiation in the Su/Hx-induced model of PH. Expression of contractile (A-E) and synthetic (F) markers were analyzed in pulmonary arteries of Nx and Su/Hx animals by RT-qPCR. All contractile markers are significantly downregulated in Su/Hx animals. Definition of genes: smooth muscle alpha actin (*Acta2*, A); calponin1 (*Cnn1*, B); myosin heavy chain 11 (*Myh11*, C); smoothelin (*Smtn*, D); transgelin (*Tagln*, E); retinol binding protein (*Rbp1*, F). Graph bars represent means±SEM. N= 5-7 rats per experimental group. *P< 0.05.

Table 1. Primers for genes in quantitative real-time PCR

Gene	Species	Accession No.	Forward Primer	Reverse Primer
Acta2	rat	NM_031004.2	5'-CTGGACGTACAACTGGTATTG-3'	5'-ATGAGGTAGTCGGTGAGAT-3'
Cnn1	rat	NM_031747.1	5'-CCAGCATGGCAAAGACAA-3'	5'-CTGTAGGCCAATGATGTTCC-3'
Gapdh	rat	NM_017008.4	5'-GACATGCCGCCTGGAGAAAC-3'	5'-AGCCCAGGATGCCCTTTAGT-3'
Myh11	rat	NM_001170600.1	5'-GCTACAAGATCGTGAAGACC-3'	5'-GTGATGCTGCTGTCTTTCT-3'
Nup133	rat	XM_008772670.2	5'-GTCTTCGATACACAAGGAGAC-3'	5'-CTTCTGCTAACAGGGACATAC-3'
Rbp1	rat	NM_012733.4	5'-TTCACCTGGAGATGAGAGC-3'	5'-TCCTCGAGACCAAGGTTATC-3'
Smtn	rat	NM_001013049.2	5'-GAGAACTGGCTACACTCTCA-3'	5'-AGTGTGGTCAACTCCTCTAC-3'
Tagln	rat	NM_031549.2	5'-TTATGAAGAAAGCCCAGGAG-3'	5'-CTCTGTTGCTGCCCATTT-3'

Definition of genes: (a) Contractile markers: *Acta2* (smooth muscle alpha 2 actin), *Cnn1*

(calponin 1), *Gapdh* (glyceraldehyde-3-phosphate dehydrogenase), *Myh11* (myosin heavy

chain 11), *Smtn* (smoothelin), *Tagln* (transgelin, also known as SM22α); (b) Synthetic marker:

*Rbp1* (retinol binding protein 1); (c) Housekeeping: *Nup133* (nucleoporin 133).

Fig. 1

Fig. 2

KCI-Induced Contraction

Pulmonary Artery **Aorta** **Mesenteric Artery**

+Endo

A B C

-Endo

□ **Normoxia**
□ **Hypoxia**
■ **Sugen**
■ **Sugen+Hypoxia**

D E F

Fig. 3

Phe-Induced Contraction

Pulmonary Artery

A

Phe Contraction (g/mg tissue)

* #

Aorta

B

Phe Contraction (g/mg tissue)

○ Normoxia
● Hypoxia
△ Sugen
▲ Sugen+Hypoxia

Mesenteric Artery

C

Phe Contraction (g/mg tissue)

D

Phe Contraction (%Max)

*† #

E

Phe Contraction (%Max)

F

Phe Contraction (%Max)

G

Phe Contraction (%96 KCl)

*† #

log [Phe] (M)

H

Phe Contraction (%96 KCl)

log [Phe] (M)

I

Phe Contraction (%96 KCl)

log [Phe] (M)

Fig. 4

Effect of Endothelium Blockade or Removal on Phe Contraction of Pulmonary Artery

Fig. 5

Endothelium-Dependent ACh-Induced Relaxation

A   **Pulmonary Artery**

B   **Aorta**

C   **Mesenteric Artery**

Fig. 6

Effect of Endothelium Blockade or Removal on ACh Relaxation of Pulmonary Artery

A Normoxia

B Hypoxia

Legend:
- ○ Control
- ● L-NAME
- △ ODQ
- ▲ -Endo

C Sugen

D Sugen+Hypoxia

x-axis: log [ACh] (M)
y-axis: %Relaxation of Phe Contraction

Fig. 7

Nitric Oxide Production

Fig. 8

Endothelium-Independent Relaxation

A **Pulmonary Artery**

B **Aorta**

C **Mesenteric Artery**

Fig. 9

Fig. 10